Eiger BioPharmaceuticals, developer of treatments for strains of hepatitis, announced that it brought in $7.1 million in first-round funding from InterWest Partners and Vivo Ventures. The Palo Alto, Calif. company will use the new money to push its lead compound — which targets hepatitis C — through its pipeline. It is also working on treatments for hepatitis D and various other viruses, it says.
Eiger spun out from research conducted on hepatitis C at Stanford University. It says the latest round of funding should give it a year’s worth of runway to continue drug testing and refinement.